Bharat Biotech eyes 1 billion doses of nasal Covid-19 vaccine in 2022

INTERNATIONAL DESK: Covaxin maker Bharat Biotech is targeting to make one billion doses annually of its intranasal vaccine in 2022 that is under clinical trials now.

The Hyderabad-based vaccine maker is also looking for global partners to manufacture and distribute the vaccine overseas. BBV154, the intranasal vaccine, can be administered as a nasal spray or a drop.

It cannot be taken at home though, but needs to be administered in a clinical setting. The adenovirus vector-based vaccine helps trigger generation of IgA antibodies that line the nasal mucosa. (Business Standard)